Eligibility for recombinant tissue plasminogen activator in acute ischemic stroke - Way to endeavor

被引:33
|
作者
Huang, Poyin [1 ]
Chen, Chun-Hung [1 ]
Yang, Yuan-Han [1 ]
Lin, Ruey-Tay [1 ]
Lin, Feng-Cheng [1 ]
Liu, Ching-Kuan [1 ]
机构
[1] Kaohsiung Med Univ, Chung Ho Mem Hosp 100, Dept Neurol, Kaohsiung 807, Taiwan
关键词
eligibility; stroke; tissue plasminogen activator; stroke code;
D O I
10.1159/000094994
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: The eligibility for recombinant tissue plasminogen activator (rtPA) is rare. We analyze the reasons for exclusion from rtPA among patients who were admitted to our hospital within 3 h. Methods: A strict protocol for hyper-acute stroke was set in a university teaching hospital. Consecutive patients activating the protocol from June 2004 to October 2005 were prospectively registered and entered into a computerized database. The patients were excluded from rtPA according to the modified exclusion criteria from the National Institute of Neurological Disorders and Stroke rtPA trial. Results: Of the 182 patients activating the protocol, only 11 (6.04%) received intravenous rtPA and 4 (2.2%) IA thrombolysis. Patients were excluded for multiple reasons, and the main reasons for exclusion were minor or improving stroke (46.15%), hypertension (35.16%), insufficient time to complete studies or onset beyond 3 h after reconfirmation (24.17%) and intracranial hemorrhage (15.93%). Of 167 excluded patients, 72 (43.11%) were excluded by a single criterion, 53 (31.73%) by 2 criteria and 29 (17.36%) by 3 criteria. The mean time from hospital arrival to presentation to a neurologist was 9.24 +/- 15.11 min (n = 164, median = 8.00, mode = 10, range = 0-65). The mean time from hospital arrival to computed tomography (CT) was 21.67 +/- 23.95 min (n = 167, median = 20.00, mode = 10, range = 4-68). Conclusion: An intrahospital stroke code was implemented to minimize intrahospital delay. However, only 11 patients received intravenous rtPA and 4 IA thrombolysis at our hospital from June 2004 to October 2005. The result brings into question the neurologist's conservative interpretation of the criteria and the necessity to clearly define some criteria. Furthermore an intrahospital stroke code should also be implemented for inpatients to maximize the eligibility for rtPA. Copyright (c) 2006 S. Karger AG, Basel.
引用
收藏
页码:423 / 428
页数:6
相关论文
共 50 条
  • [31] Thrombolytic therapy with intravenous recombinant tissue plasminogen activator in Japanese older patients with acute ischemic stroke: Fukuoka Stroke Registry
    Matsuo, Ryu
    Kamouchi, Masahiro
    Ago, Tetsuro
    Hata, Jun
    Shono, Yuji
    Kuroda, Junya
    Wakisaka, Yoshinobu
    Sugimori, Hiroshi
    Kitazono, Takanari
    GERIATRICS & GERONTOLOGY INTERNATIONAL, 2014, 14 (04) : 954 - 959
  • [32] Hyperacute thrombolysis with recombinant tissue plasminogen activator of acute ischemic stroke: Feasibility and effectivity from an Indian perspective
    Sharma, S. R.
    Sharma, Nalini
    ANNALS OF INDIAN ACADEMY OF NEUROLOGY, 2008, 11 (04) : 221 - 224
  • [33] Pharmacist Participation in Acute Ischemic Stroke Decreases Door-to-Needle Time to Recombinant Tissue Plasminogen Activator
    Rech, Megan A.
    Bennett, Stephanie
    Donahey, Elisabeth
    ANNALS OF PHARMACOTHERAPY, 2017, 51 (12) : 1084 - 1089
  • [34] Hemorrhagic Transformation After Tissue Plasminogen Activator Treatment in Acute Ischemic Stroke
    Liu, Chengli
    Xie, Jie
    Sun, Shanshan
    Li, Hui
    Li, Tianyu
    Jiang, Chao
    Chen, Xuemei
    Wang, Junmin
    Le, Anh
    Wang, Jiarui
    Li, Zhanfei
    Wang, Jian
    Wang, Wei
    CELLULAR AND MOLECULAR NEUROBIOLOGY, 2022, 42 (03) : 621 - 646
  • [35] Worldwide reported use of IV tissue plasminogen activator for acute ischemic stroke
    Berkowitz, Aaron L.
    Mittal, Manoj K.
    McLane, Hannah C.
    Shen, Gordon C.
    Muralidharan, RajaNandini
    Lyons, Jennifer L.
    Shinohara, Russell T.
    Shuaib, Ashfaq
    Mateen, Farrah J.
    INTERNATIONAL JOURNAL OF STROKE, 2014, 9 (03) : 349 - 355
  • [36] Hemorrhagic Transformation After Tissue Plasminogen Activator Treatment in Acute Ischemic Stroke
    Chengli Liu
    Jie Xie
    Shanshan Sun
    Hui Li
    Tianyu Li
    Chao Jiang
    Xuemei Chen
    Junmin Wang
    Anh Le
    Jiarui Wang
    Zhanfei Li
    Jian Wang
    Wei Wang
    Cellular and Molecular Neurobiology, 2022, 42 : 621 - 646
  • [37] Utilization of Intravenous Tissue Plasminogen Activator and Reasons for Nonuse in Acute Ischemic Stroke in Saudi Arabia
    Al Khathaami, Ali M.
    Al Bdah, Bayan
    Tarawneh, Maisoun
    Alskaini, Mohammed
    Alotaibi, Faris
    Alshalan, Abdulaziz
    Almuhraj, Mohammed
    Aldaham, Daham
    Alotaibi, Nasser
    JOURNAL OF STROKE & CEREBROVASCULAR DISEASES, 2020, 29 (05)
  • [38] Findings from the reanalysis of the NINDS tissue plasminogen activator for acute ischemic stroke treatment trial
    Ingall, TJ
    O'Fallon, WM
    Asplund, K
    Goldfrank, LR
    Hertzberg, VS
    Louis, TA
    Christianson, TJH
    STROKE, 2004, 35 (10) : 2418 - 2424
  • [39] RUPTURE OF AN OCCULT INTRACRANIAL MYCOTIC ANEURYSM AFTER INTRAVENOUS THROMBOLYSIS WITH RECOMBINANT TISSUE PLASMINOGEN ACTIVATOR FOR ACUTE ISCHEMIC STROKE
    Glenn, Jared
    Strecker-McGraw, Margaret
    McGraw, Ian
    Jabbar, Karim
    James, Nathan A.
    Stone, C. Keith
    JOURNAL OF EMERGENCY MEDICINE, 2017, 53 (05) : 717 - 721
  • [40] Update on the effects of treatment with recombinant tissue-type plasminogen activator (rt-PA) in acute ischemic stroke
    Bonaventura, Aldo
    Montecucco, Fabrizio
    Dallegri, Franco
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2016, 16 (11) : 1323 - 1340